Recently, Yang et al. reported that sulforaphane (SFN) restrained HFD-induced NAFLD through decreasing the expression levels of ASC and casp1 mRNA and IL-1β production in the liver (64). This evidence concerns the gene CASP1 and metabolic dysfunction-associated steatotic liver disease.